Global Epidemiology of Drug-Induced Liver Injury (DILI)
- 26 Downloads
Purpose of Review
Drug-induced liver injury (DILI) is not an uncommon liver disease in many parts of the world. DILI is one of the most common causes of acute liver failure in most countries. The current review summarizes the global epidemiology of DILI.
The number need to harm in terms of DILI due to amoxicillin-clavulanate was approximately 1 out 2300, but was higher for azathioprine (1 out of 133) and infliximab (1 out of 148). A retrospective Chinese study showed the highest rate of DILI in hospitalized patients with an incidence of approximately 24 patients per 100,000 annually with a more favorable prognosis in the DILI cohort than previously reported from Europe, the USA, and Asia.
Although large DILI registries from Europe and the USA have collected much data, more prospective studies with continual enrollment are needed particularly as new therapies such as immune modulatory and oncological medications with longer half-lives and latencies come to market.
KeywordsDILI Hepatotoxicity Epidemiology Incidence Prognosis Global
Compliance with Ethical Standards
Conflict of Interest
Einar S. Björnsson declares no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Garcia Rodriguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research database in the United Kingdom. Pharmacotherapy. 1997;17:721–8.Google Scholar
- 15.• Vega M, Verma M, Beswick D, Bey S, Hossack J, Merriman N, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf. 2017;40:783–7. An important first population-based study of DILI in the USA. CrossRefGoogle Scholar
- 20.Ohmori S, Shiraki K, Inoue H, Okano H, Yamanaka T, Deguchi M, et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology. 2003;50:1531–4.Google Scholar
- 21.Zhao P, Wang C, Liu W, Chen G, Liu X, Wang X, et al. Causes and outcomes of acute liver failure in China. PLoS One. 2014;22(8):e80991.Google Scholar
- 26.•• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports. Hepatology. 2016;63:590–603. Critical analysis of published case reports of DILI. Only 353 drugs marketed in the USA had convincingly been linked to liver injury. CrossRefGoogle Scholar
- 28.• Stolz A, Navarro V, Hayashi PH, Fontana RJ, Barnhart HX, Gu J, et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019;49:1195–204. An important observational study shows that ingested products often contained anabolic steroids not identified on the label.CrossRefGoogle Scholar
- 30.Antonazzo IC, Poluzzi E, Forcesi E, Riise T, Bjornevik K, Baldin E, et al. Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler. 2018 Sep;19:1352458518799598.Google Scholar
- 44.Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol. 2005;39:64–7.Google Scholar
- 59.Ou P, Chen Y, Li B, Zhang M, Liu X, Li F, et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus. 2015;4:802. https://doi.org/10.1186/s40064-015-1600-8.eCollection2015.CrossRefGoogle Scholar
- 60.•• Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol. 2013;25:825–9. The largest DILI cohorted reported to date. Patients had better prognosis than previously reported in other DILI cohorts. CrossRefGoogle Scholar